spacer
home > ebr > winter 2002 > from genes to drugs
PUBLICATIONS
European Biopharmaceutical Review

From Genes to Drugs

One of the biggest obstacles in the development of cancer therapeutics is the sheer complexity of the problem. Cancer may result from a large number of genetic and molecular defects, or combination of these defects, giving rise to loss of cell cycle checkpoints and unregulated cell division. Even individual tumours may exhibit heterogeneous phenotypes at the cellular level. The inherent genetic instability of cancer cells may also add to the problem, enabling them to continue to change during treatment and effectively presenting a moving target.The majority of anti-cancer therapeutics currently in use were discovered due to their ability to kill fast-growing cancer cells. Unfortunately, these often cause severe side effects due to their impact on other fast-growing cells in the body. There is, therefore, a need to design drugs that target a specific pathogenic pathway and to base the design of the drug upon the structure of its protein target.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Bob Jackson, Executive Director of R&D at Cyclacel Dr Robert Jackson joined Cyclacel in January 2001. Prior to this he was Research and Development Director at Celltech Group plc and Executive Director, R&D and Chief Operating Officer at Chiroscience Group plc.
Before these appointments, Dr Jackson was Vice President of R&D at Agouron Pharmaceuticals and headed cancer research at DuPont Pharmaceuticals and Warner-Lambert Company. Dr Jackson has been instrumental in the discovery and development of several marketed drugs used to treat cancer, HIV and other serious diseases. He holds a BA from the University of Cambridge and a PhD from the University of London, Institute of Cancer Research.

spacer
Dr Bob Jackson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo received the Customer Satisfaction Management Certificate (ISO 10002).

Turkish Cargo, the fastest growing air cargo brand in the world, obtained the "Customer Satisfaction Management Certificate" (ISO 10002) and developed the Cargo Customers Feedback Management Policy accordingly.
More info >>

White Papers

8 Ways To Reduce Tablet Manufacturing Costs

Natoli Engineering Company, Inc.

Itís no surprise that in todayís economy, companies are facing budget cuts across the board. In an effort to address these challenges, this list of 8 Ways to Reduce Tablet Manufacturing Costs was compiled.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India forhigh quality, low   cost pharma solutions, CPhI & P-MEC Indiais the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from Indiaís pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement